Ondine to present research demonstrating high efficacy against Extensively Drug-Resistant (XDR) bacteria at ICPIC 2023, Geneva
VANCOUVER, BC / ACCESSWIRE / September 14, 2023 / Canadian life sciences company Ondine Biomedical Inc. (LON:OBI) is presenting new research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demonstrating high efficacy of its patented photodisinfection technology against extensively drug-resistant (XDR) bacteria. Ondine is the global leader in developing photodisinfection-based therapies for the prevention of healthcare-associated infections.
The study demonstrates that Ondine's Steriwave™ photodisinfection technology is highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) pathogens. Gram-negative bacteria, such as Escherichia coli, Pseudomonas aeruginosa, Enterobacter cloacae, and Klebsiella pneumoniae cause many serious healthcare-associated infections. The research underlines the potential for Steriwave to become a rapid, broad-spectrum, bactericidal alternative to antibiotics.
Antimicrobial resistance (AMR) poses an urgent global public health threat resulting in 1.27 million annual deaths worldwide, and is predicted to become one of the largest threats to human health in the coming years.[i] The emergence and worldwide spread of extensively drug-resistant (XDR) microbes is highly concerning, as infections caused by these pathogens are virtually untreatable because they are proving resistant to almost all approved antimicrobial agents.[ii],[iii]
Dr. Nicolas Loebel, Ondine's CTO and President, commented: "Overuse of antibiotics over decades has caused adaptation in many microbes, and we now see multidrug resistance (MDR) evolving into extensive drug resistance (XDR) in bacteria, rendering even the most powerful combination of drugs ineffective. We believe photodisinfection can play a significant role in cost-effectively combatting these drug-resistant pathogens and reducing global reliance on antibiotics. We know of no other antimicrobial that can match the performance, safety, and cost benefits of photodisinfection."
Ondine's Steriwave system employs patented technology that rapidly and safely eliminates bacteria, fungi, and viruses located on human tissues. Ondine is a previous winner of an ICPIC Innovation Award of Excellence for its clinical and pre-clinical work demonstrating photodisinfection efficacy against SARS-CoV-2. In 2013, Canada's Vancouver General Hospital was also awarded the ICPIC Innovation Award of Excellence for its universal pre-surgical nasal decolonization program using Ondine's Steriwave system, significantly reducing post-surgical infection rates and improving outcomes for thousands of surgical patients.
The poster presentation, "Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram-Negative Isolates With Novel Antibiotic Resistance Factors", is being presented at the 7th International Consortium on Prevention & Infection Control (ICPIC) from 1:00 pm to 2:00 pm CET on Thursday 14 September 2023. ICPIC is a leading international conference on the prevention of healthcare-associated infections and the control of antimicrobial resistance around the world.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.
| Ondine Biomedical Inc. | |
| Carolyn Cross, CEO | +001 (604) 665 0555 |
| Singer Capital Markets (Nominated Adviser and Joint Broker) | |
| Aubrey Powell, Asha Chotai, Sam Butcher | +44 (0)20 7496 3000 |
| RBC Capital Markets (Joint Broker) | |
| Rupert Walford, Kathryn Deegan | +44 (0)20 7653 4000 |
| Vane Percy & Roberts (Media Contact) | |
| Simon Vane Percy, Amanda Bernard | +44 (0)77 1000 5910 |
[i] Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet (London, England), 399(10325), 629-655. https://doi.org/10.1016/S0140-6736(21)02724-0
[ii] Ryding, S. "What are Extensively Drug Resistant (XDR) Bacteria?" News Medical Life Sciences. Nov. 16, 2021. https://www.news-medical.net/health/What-are-Extensively-Drug-Resistant-(XDR)-Bacteria.aspx
[iii] CDC. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Atlanta, GA: U.S.
Department of Health and Human Services, CDC; 2022.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Ondine Biomedical Inc.